中文 |         ENGLISH

 

Search
Copyright © 2017 ZHEJIANG LEPU PHARMACEUTICAL CO.,LTD.
浙ICP备17026965号 Powered by www.300.cn
Messages | Contact us

ABOUT US

Memorabilia

 
· In January 2010, the brand “Kanglide” was rated as Zhejiang Famous Trademark by Zhejiang Administration for Industry and Commerce.
 
· In 2010, the company was selected as a patent demonstration enterprise in Zhejiang Province.
 
· In 2010, the sertraline hydrochloride green chemical project was listed in major provincial science and technology projects.
 
· In 2010, Lovastatin won the third prize of outstanding new industrial product and new technology of Zhejiang Province.
 
· In 2010, the company was awarded the Advanced Collective of Appraisal Activity of Zhejiang Association for Science and Technology.
 
· In January 2010, the API Atomvastatin Calcium was approved for drug registration.
 
· In February 2010, the API fexofenadine hydrochloride and fexofenadine hydrochloride capsules were approved for drug registration.
 
· In March 2010, the API doxazosin mesylate and atorvastatin calcium passed the GMP certification of drugs organized by Zhejiang Provincial Center for Drug Certification.
 
· In October 2010, the API sertraline hydrochloride, bromhexine hydrochloride and fexofenadine hydrochloride passed the GMP certification of drugs organized by Zhejiang Provincial Center for Drug Certification.
 
· In November 2010, a method for preparing amorphous calcium statin using crystalline atorvastatin sodium won the national invention patent certificate.
 
· In December 2010 Norfloxacin synthesis process won the national invention patent certificate.
 
· In March 2011, the first trade union committee was established.
 
· In April 2011, atorvastatin sodium, atorvastatin intermediate L-1, rosuvastatin intermediate R-1.5 and rosuvastatin intermediate RJS-3 passed the US FDA site CGMP inspection (re-certification).
 
· In May 2011, the company was recognized as the first batch of "Workstations of academicians and experts in Taizhou” by the Taizhou City.
 
· In August 2011, the carbapenem antibiotic Meropenem was listed in the National Torch Program Project.
 
· In August 2012, the tablets and capsules passed the delayed on-site inspection of GMP certificates.
 
· In September 2012, the company was recognized as"Workstations of academicians and experts in Zhejiang Province” by the Leading Group of Talents Work of Zhejiang Provincial Party Committee.
 
· In October 2012, the State-owned Assets Supervision and Administration Commission of Zhejiang Provincial People's Government issued the Reply on the Reorganization Plan of Zhejiang Hongyuan Pharmaceutical Co., Ltd. and Zhejiang Neo-Dankong Pharmaceutical Co., Ltd.(Zhejiang State-owned Assets Reform No. 22 (2012), and approved the reorganization plan, to achieve a powerful combination with Zhejiang property group.
 
· In December 2012, Norfloxacin passed the site GMP inspection of South Korea KFDA.
 
· In February 2013, Norfloxacin passed site CGMP inspection of Jazmp, Slovenia.
 
· In April 2013, Atorvastatin Calcium tablets were approved for drug registration.
 
· In December 4, 2013, “A method of preparing Linezolid crystal type I using suspension crystallization ” developed by the company won the national invention patent certificate.
 
· In February 2014, the company's preparations (tablets and capsules) passed the new GMP certification.
 
· On March 6, 2014, the company established the first Neo-Dankong Order Class in Department of Biological and Chemical Engineering, Taizhou Vocational and Technical College
 
· On August 30, 2014, the project "Key Technologies and Industrialization of Atomvastatin Calcium-Enzymatic Synthesis" passed the appraisal of scientific and technological achievements in Hangzhou.
 
· On August 25-29, 2014, the company's products atorvastatin calcium, rosuvastatin calcium and other BPCs and intermediates accepted the CGMP on-site inspection by US inspectors, and passed the FDA re-certification again by “0483”.
 
· In September 2014, a total of 102 party members participate in physical examination. Our company was listed in the China's pharmaceutical industries with main business income ranked top 500 (282), and with profit ranked top 500 (335).
 
· On January 24, 2015, Zhejiang Neo-Dankong Pharmaceutical Co., Ltd. held the first board of directors of the sixth session, and elected the new board of directors. Wei Zhanjiang was elected as chairman, and HongHuaBin was elected as general manager.
 
· On January 9, 2015, Deputy Director of Provincial Department of Science and Technology and other leaders visited our company, and inspected our company's reform of social science and technology project. The general manager of our company made work report and accompanied the visit.
 
· In April 2015, the company passed the re-identification of provincial high and new technology enterprise.